Harriet Louise Lancaster

Dr. Harriet Louise Lancaster

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2022 in Journal of Internal Medicine
Verified
Journal Article
Open access
HLHarriet Louise Lancaster
Harriet Louise Lancaster
MHMarjolein A. Heuvelmans
Marjolein A. Heuvelmans
MOMatthijs Oudkerk
Matthijs Oudkerk
Lung cancer causes more deaths than breast, cervical, and colorectal cancer combined. Nevertheless, population‐based lung cancer screening is still not considered standard practice in most countries worldwide. Early lung cancer detection leads to better survival outcomes: patients diagnosed with stage 1A lung cancer have a >75% 5‐year survival rate, compared to <5% at stage 4. Low‐dose computed tomography (LDCT) thorax imaging for the secondary prevention of lung cancer has been studied at length, and has been shown to significantly reduce lung cancer mortality in high‐risk populations. The US National Lung Screening Trial reported a 20% overall reduction in lung cancer mortality when comparing LDCT to chest X‐ray, and the Nederlands‐Leuvens Longkanker Screenings Onderzoek (NELSON) trial more recently reported a 24% reduction when comparing LDCT to no screening. Hence, the focus has now shifted to implementation research. Consequently, the 4‐IN‐THE‐LUNG‐RUN consortium based in five European countries, has set up a large‐scale multicenter implementation trial. Successful implementation of and accessibility to LDCT lung cancer screening are dependent on many factors, not limited to population selection, recruitment strategy, computed tomography screening frequency, lung‐nodule management, participant compliance, and cost effectiveness. This review provides an overview of current evidence for LDCT lung cancer screening, and draws attention to major factors that need to be addressed to successfully implement standardized, effective, and accessible screening throughout Europe. Evidence shows that through the appropriate use of risk‐prediction models and a more personalized approach to screening, efficacy could be improved. Furthermore, extending the screening interval for low‐risk individuals to reduce costs and associated harms is a possibility, and through the use of volumetric‐based measurement and follow‐up, false positive results can be greatly reduced. Finally, smoking cessation programs could be a valuable addition to screening programs and artificial intelligence could offer a solution to the added workload pressures radiologists are facing.

28 December 2024 in European Journal of Cancer
Verified
Journal Article
Open access
AWAnna N.H. Walstra
Anna N.H. Walstra
HLHarriet Louise Lancaster
Harriet Louise Lancaster
MHMarjolein A. Heuvelmans
Marjolein A. Heuvelmans
CACarlijn M. van der Aalst
Carlijn M. van der Aalst
JHJuul Hubert
Juul Hubert
MOMatthijs Oudkerk
Matthijs Oudkerk
Lung cancer screening (LCS) with low-dose CT (LDCT) reduces lung-cancer-related mortality in high-risk individuals. AI can potentially reduce radiologist workload as first-read-filter by ruling-out negative cases. The feasibility of AI as first reader was evaluated in the European 4-IN-THE-LUNG-RUN (4ITLR) trial, comparing its negative-misclassifications (NMs) to those of radiologists and the impact on referral rates. NMs were collected from 3678 baseline LDCTs of the 4ITLR-dataset. LDCTs were read independently by radiologists and dedicated AI software (AVIEW-LCS, v1.1.42.92, Coreline-Soft, Seoul, Korea). A case was designated as NM when nodules > 100 mm3 were present and either radiologist or AI gave a negative-classification (only nodules 300 mm3) classification, warranting referral for clinical-workup. Overall, there were 102 referrals (2.8 %) at baseline. Of the 3678 baseline scans, 438 NMs (11.9 %) were identified (age individuals: 68 (IQR: 64-73) years, 241 men); 31 (0.8 %) by AI and 407 (11.1 %) by radiologists. Among the 31 AI-NMs, 3 were classified positive and 28 indeterminate. Among the 407 radiologist-NMs, 4 were classified positive, and 403 were indeterminate, of which 8 were classified positive after receiving a three-month follow-up CT. Radiologists, as first reader, would have led to 12/102 (11.8 %) missed referrals, higher than the 3/102 (2.9 %) of AI. This study showed AI outperforms radiologists with significantly less NMs and therefore shows promise as first reader in a LCS program at baseline, by independently ruling-out negative cases without substantially increasing the risk of missed clinical referrals.

30 January 2025 in European Journal of Cancer
Verified
Journal Article
Closed access
JMJames L. Mulshine
James L. Mulshine
BPBruce Pyenson
Bruce Pyenson
CHCheryl Healton
Cheryl Healton
CACarolyn Aldige
Carolyn Aldige
RARiccardo S. Avila
Riccardo S. Avila
MOMatthijs Oudkerk
Matthijs Oudkerk

25 February 2025 in European Journal of Cancer
Verified
Journal Article
Open access
HLHarriet Louise Lancaster
Harriet Louise Lancaster
BJBeibei Jiang
Beibei Jiang
MDMichael P.A. Davies
Michael P.A. Davies
JGJan Willem C. Gratama
Jan Willem C. Gratama
MSMario Silva
Mario Silva
MOMatthijs Oudkerk
Matthijs Oudkerk
Artificial intelligence (AI) could reduce lung cancer screening computer tomography (CT)-reading workload if used as a first-reader, ruling-out negative CT-scans at baseline. Evidence is lacking to support AI performance when compared to gold-standard lung cancer outcomes. This study validated the performance of a commercially available AI software in the UK lung cancer screening (UKLS) trial dataset, with comparison to human reads and histological lung cancer outcomes, and estimated CT-reading workload reduction. 1252 UKLS-baseline-CT-scans were evaluated independently by AI and human readers. AI performance was evaluated on two-levels. Firstly, AI classification and individual reads were compared to a EU reference standard (based on NELSON2.0-European Position Statement) determined by a European expert panel blinded from individual results. A positive misclassification was defined as a nodule positive read ≥ 100mm3 and no/<100mm3 nodules in the expert read; A negative misclassification was defined as a nodule negative read, whereas an indeterminate or positive finding in the expert read. Secondly, AI nodule classification was compared to gold-standard histological lung cancer outcomes. CT-reading workload reduction was calculated from AI negative CT-scans when AI was used as first-reader. Expert panel reference standard reported 815 (65 %) negative and 437 (35 %) indeterminate/positive CT-scans in the dataset of 1252 UKLS-participants. Compared to the reference standard, AI resulted in less misclassification than human reads, NPV 92·0 %(90·2 %-95·3 %). On comparison to gold-standard, AI detected all 31 baseline-round lung cancers, but classified one as negative due to the 100mm3 threshold, NPV 99·8 %(99·0 %-99·9 %). Estimated maximum CT-reading workload reduction was 79 %. Implementing AI as first-reader to rule-out negative CT-scans, shows considerable potential to reduce CT-reading workload and does not lead to missed lung cancers.

6 March 2025 in European Journal of Cancer
Verified
Journal Article
Closed access
JMJames L. Mulshine
James L. Mulshine
RARicardo S. Avila
Ricardo S. Avila
MSMario Silva
Mario Silva
CACarolyn Aldige
Carolyn Aldige
TBTorsten Blum
Torsten Blum
DYDavid F. Yankelelvitz
David F. Yankelelvitz

22 February 2025 in European Journal of Cancer
Verified
Journal Article
Open access
HLHarriet Louise Lancaster
Harriet Louise Lancaster
AWAnna N.H. Walstra
Anna N.H. Walstra
KMKyle Myers
Kyle Myers
RARicardo S. Avila
Ricardo S. Avila
JGJan Willem C. Gratama
Jan Willem C. Gratama
MOMatthijs Oudkerk
Matthijs Oudkerk
Reduction in lung cancer mortality is achievable through low dose computed tomography (LDCT) screening in high-risk individuals. Many countries are progressing from local LDCT screening studies to national screening programs. Implementation of effective large-scale screening programs is complex and requires a multi-disciplinary approach. A recent overview of the technical aspects of implementing high quality LDCT for screening resulted from the inaugural international expert meeting of the Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment (AGILE). This covers the most important aspects of the CT imaging process: standardisation in CT image acquisition and interpretation, CT protocol management, technology developments and minimal requirements, integration of lung cancer biomarkers, and the role of AI in CT lung nodule detection, segmentation, and classification, and related data security issues.